Navigation Links
Treatment Combo for Pancreatic Cancer Has Limited Benefit
Date:3/4/2008

Chemo/chemoradiation therapy extended survival but not significantly

TUESDAY, March 4 (HealthDay News) -- In patients who had surgery for pancreatic cancer, adding the chemotherapy drug gemcitabine to chemoradiation prolonged survival, but the improvement was not statistically significant, a new study finds.

Among patients who have surgery to remove pancreatic cancer, there is a 50 percent to 85 percent rate of local relapse and a five-year survival rate of less than 20 percent, according to background information in the study.

This makes the combination of added postoperative chemotherapy and radiation an important consideration. Previous research has shown that gemcitabine is more effective than the drug fluorouracil at improving patient outcomes.

This study examined whether the addition of gemcitabine to the supplemental treatment of fluorouracil chemoradiation improved survival in patients who had a portion of their pancreas removed as a treatment for pancreatic cancer.

During the study, the 451 patients received either chemotherapy with gemcitabine (221) or with fluorouracil (230) for three weeks prior to chemoradiation therapy and for 12 weeks after chemoradiation therapy (with fluorouracil).

Among the 388 patients with pancreatic head tumors, those in the gemcitabine group had a median (midpoint) survival of 20.5 months and a three-year survival rate of 31 percent, compared to 16.9 months and 22 percent among those in the fluorouracil group. The rates of certain level (grade 4) of hematologic (abnormalities in blood cell counts) toxicity were 1 percent in the fluorouracil group and 14 percent in the gemcitabine group.

There were no differences in neutropenia (a blood disorder), infection, or in the ability to complete chemotherapy or radiation therapy.

"The addition of gemcitabine to (supplemental) fluorouracil-based chemoradiation was associated with a survival benefit for patients with resected pancreatic cancer, although this improvement was not statistically significant," the study authors concluded.

The study was published in the March 5 issue of the Journal of the American Medical Association.

More information

The American Cancer Society has more about pancreatic cancer.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, March 4, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New potential drug target for the treatment of atherosclerosis
2. New Treatment for Lazy Eye Shows Promise
3. New target for cancer therapy may improve treatment for solid tumors
4. ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old
5. Customized treatments for sepsis lower treatment time and reduce length of ICU stays
6. FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
7. Geriatric Oncology Consortium (GOC) Announces Tampa Bay Road Rally to Raise Awareness for the Treatment of Seniors With Cancer
8. Comparison of antipsychotic treatments in adolescents with schizophrenia
9. Treatment for disease that affects estimated 1 in 2000 children gets them to eat again
10. FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old
11. Biomarkers for Mood May Alter Psychiatric Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology: